Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug

Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Agent Who Need Emergent Temporary Catheter Insertion for Hemodialysis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01841515

Enrollment

Registered

2013-04-26

Start date

2012-08-31

Completion date

2013-04-30

Last updated

2013-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding, Dyspnea, Tachycardia

Brief summary

Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The investigators designed a prospective study to evaluate the effect of desmopressin on platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic patients who were taking antiplatelet drugs.

Interventions

DRUGDesmopressin administration

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* adult uremic patients with one or more antiplatelet medication, * prolonged collagen/epinephrine (CEPI) closure time, * need for emergent hemodialysis and * subsequent catheter insertion

Exclusion criteria

* acute coronary syndrome, * hemophilia, and nephrogenic diabetes insipidus, * allergy against desmopressin

Design outcomes

Primary

Measure	Time frame	Description
collagen-epinephrine closure time	1 hour	In vitro closure time (CT), measured using a platelet function analyzer (PFA)-100, is a relatively new tool for investigation of primary hemostasis. This system has been shown to be efficacious in evaluating abnormalities of primary hemostasis.

Secondary

Measure	Time frame	Description
Bleeding after procedure	1-4 hr after procedure	we observe incidence of bleeding complication after procedure

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026